JP2014508759A - シアリル化抗体の生産の方法 - Google Patents

シアリル化抗体の生産の方法 Download PDF

Info

Publication number
JP2014508759A
JP2014508759A JP2013554892A JP2013554892A JP2014508759A JP 2014508759 A JP2014508759 A JP 2014508759A JP 2013554892 A JP2013554892 A JP 2013554892A JP 2013554892 A JP2013554892 A JP 2013554892A JP 2014508759 A JP2014508759 A JP 2014508759A
Authority
JP
Japan
Prior art keywords
antibody
seq
domain
sequence
antiabeta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013554892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508759A5 (OSRAM
Inventor
ブランシユ，フランシス
カムロン，ベアトリス
ジユネ，ブリユノ
スブリエ，フアブリエンヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2014508759A publication Critical patent/JP2014508759A/ja
Publication of JP2014508759A5 publication Critical patent/JP2014508759A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013554892A 2011-02-24 2012-02-23 シアリル化抗体の生産の方法 Pending JP2014508759A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305200 2011-02-24
EP11305200.5 2011-02-24
EP11306090.9 2011-09-01
EP11306090 2011-09-01
PCT/EP2012/053065 WO2012113863A1 (en) 2011-02-24 2012-02-23 Method of production of sialylated antibodies

Publications (2)

Publication Number Publication Date
JP2014508759A true JP2014508759A (ja) 2014-04-10
JP2014508759A5 JP2014508759A5 (OSRAM) 2015-02-19

Family

ID=45774189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013554892A Pending JP2014508759A (ja) 2011-02-24 2012-02-23 シアリル化抗体の生産の方法

Country Status (6)

Country Link
US (1) US20140046032A1 (OSRAM)
EP (1) EP2678357A1 (OSRAM)
JP (1) JP2014508759A (OSRAM)
AR (1) AR085302A1 (OSRAM)
TW (1) TW201241182A (OSRAM)
WO (1) WO2012113863A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515524A (ja) * 2017-01-31 2020-05-28 サノフイＳａｎｏｆｉ ベータアミロイドペプチドのプロトフィブリル形態に特異的な抗体の神経細胞保護作用
JP2021522216A (ja) * 2018-04-20 2021-08-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 高度にシアル化された自己抗体およびその使用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
AU2014249224B2 (en) 2013-03-11 2019-01-17 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
EP3719122A1 (en) 2013-05-02 2020-10-07 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
CN105324487B (zh) 2013-05-29 2020-01-17 豪夫迈·罗氏有限公司 唾液酸化的定量控制
WO2015001033A1 (en) 2013-07-05 2015-01-08 F. Hoffmann-La Roche Ag Process for the mono- and bi-sialylation of glycoproteins employing n-terminally truncated beta-galactoside alpha-2,6-sialyltransferase mutants
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US20160257754A1 (en) * 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CN108064266A (zh) 2014-07-21 2018-05-22 格利科斯芬兰公司 在丝状真菌中具有哺乳动物样n-聚糖的糖蛋白的制备
EP3037527A1 (en) * 2014-12-22 2016-06-29 F. Hoffmann-La Roche AG Sialyltransferase without CMP-dependent sialidase activity
CN107429237B (zh) 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
JP7516047B2 (ja) 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
AU2020253455A1 (en) 2019-04-03 2021-11-04 Genzyme Corporation Anti-alpha beta TCR binding polypeptides with reduced fragmentation
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CA3237662A1 (en) * 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
WO2025101901A1 (en) * 2023-11-10 2025-05-15 The Board Of Trustees Of The Leland Stanford Junior University Use of sialylated ivig or igg fc region-containing protein for preventing or treating respiratory virus diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504569A (ja) * 2005-06-30 2009-02-05 セントカー・インコーポレーテツド 向上した治療活性をもつ方法および組成物
JP2010510801A (ja) * 2006-11-28 2010-04-08 サントリオン 生物学的活性が向上した修飾可溶性ＦＧＦ受容体Ｆｃ融合物
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
WO2010130946A1 (fr) * 2009-05-12 2010-11-18 Sanofi-Aventis Anticorps humanises spécifiques de la forme protofibrillaire du peptide béta-amyloide

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
EP1427828B1 (en) 2001-09-14 2010-04-28 Cellectis Random integration of a polynucleotide after in vivo linearization
AU2004208031B2 (en) 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
CA2626556C (en) 2005-10-21 2016-05-10 Genzyme Corporation Antibody-based therapeutics with enhanced adcc activity
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
ES2454253T3 (es) 2005-12-12 2014-04-10 Ac Immune S.A. Anticuerpos monoclonales específicos de beta A 1-42 con propiedades terapéuticas
MX2008012843A (es) 2006-04-05 2009-01-19 Univ Rockefeller Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
AU2007317755A1 (en) 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2009032661A1 (en) 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
RU2571859C2 (ru) 2007-10-05 2015-12-20 Дженентек, Инк. Применение антитела против амилоида-бета при глазных заболеваниях
JP2011500059A (ja) 2007-10-15 2011-01-06 セントコア・オーソ・バイオテツク・インコーポレーテツド ヒト抗アミロイド抗体、組成物、方法及び使用
EP2205752B1 (en) 2007-10-25 2016-08-10 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
EP2226081A4 (en) 2007-10-25 2011-10-12 Univ Kagoshima PEPTIDE VACCINE WITH A MIMIC MOLECULE OF AMYLOID PEPTIDE
EP2224000B1 (en) 2007-10-29 2020-05-13 TAO Health Life Pharma Co., Ltd. Antibody and use thereof
KR101581733B1 (ko) 2007-11-16 2015-12-31 더 락커펠러 유니버시티 원섬유 형태의 베타­아밀로이드 단백질에 대해 특이적인 항체
BRPI0819916A2 (pt) 2007-12-11 2015-05-19 Glaxo Group Ltd Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504569A (ja) * 2005-06-30 2009-02-05 セントカー・インコーポレーテツド 向上した治療活性をもつ方法および組成物
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2010510801A (ja) * 2006-11-28 2010-04-08 サントリオン 生物学的活性が向上した修飾可溶性ＦＧＦ受容体Ｆｃ融合物
WO2010130946A1 (fr) * 2009-05-12 2010-11-18 Sanofi-Aventis Anticorps humanises spécifiques de la forme protofibrillaire du peptide béta-amyloide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 286, JPN6017006279, 2001, pages 243 - 249, ISSN: 0003505805 *
SCIENCE, vol. 320, JPN6017006281, 2008, pages 373 - 376, ISSN: 0003505806 *
THE JOURNAL OF IMMUNOLOGY, vol. 157, JPN6015007484, 1996, pages 4963 - 4969, ISSN: 0003226087 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515524A (ja) * 2017-01-31 2020-05-28 サノフイＳａｎｏｆｉ ベータアミロイドペプチドのプロトフィブリル形態に特異的な抗体の神経細胞保護作用
JP2021522216A (ja) * 2018-04-20 2021-08-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 高度にシアル化された自己抗体およびその使用

Also Published As

Publication number Publication date
US20140046032A1 (en) 2014-02-13
WO2012113863A1 (en) 2012-08-30
AR085302A1 (es) 2013-09-18
TW201241182A (en) 2012-10-16
EP2678357A1 (en) 2014-01-01

Similar Documents

Publication Publication Date Title
JP2014508759A (ja) シアリル化抗体の生産の方法
JP7357382B2 (ja) 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
Vattepu et al. Sialylation as an important regulator of antibody function
AU2016372934B2 (en) Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
DK1896071T3 (en) Methods and compositions with increased therapeutic activity
AU2017285764B2 (en) Anti-myostatin antibodies and methods of use
CA2674239C (en) Methods and vectors for generating asialylated immunoglobulins
US20100189714A1 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2963760A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR20100074220A (ko) Ｃｄｒ의 아미노산 치환에 의해 항체의 등전점을 개변하는 방법
CN103582650A (zh) 用于制备具有改善性质的含Fc多肽的方法
WO2008057634A2 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2024518545A (ja) Ｔｒｅｍ２のアゴニスト
TWI781973B (zh) 用於以活體外進行抗體糖基化工程之方法
CN119685431A (zh) 用于体外糖工程化抗体的方法
MX2013015061A (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso para el tratamiento del cancer.
CN114181312A (zh) 半乳糖改造的免疫球蛋白1抗体
JP2010512306A (ja) 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
NZ597651A (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
KR20250094703A (ko) 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
HK40011892B (zh) 用於体外糖工程化抗体的酶的再使用
TW201305336A (zh) 具作用功能的抗ｃｘｃｒ４抗體及其供治療癌症之用途
HK1191032A (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141222

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20151207

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161220

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170224